Overview

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The study explores whether Ceramide NanoLiposome (CNL) combined with other conventional cancer-fighting drugs makes them work better.
Phase:
Phase 1
Details
Lead Sponsor:
Keystone Nano, Inc
Collaborators:
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
University of Virginia